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The biochemical and morphological modifications that Triton and prednisolone produce on galactosamine hepatitis in rats were studied. —
Determinations of acid phosphatase, N-acetyl-ß-glucosaminidase, cathepsin D, and acid carboxypeptidase in tissue fractions indicate that
they can be liberated from lysosomes when galactosamine and Triton are given either alone or simultaneously; in the latter case the alter-
ations are more severe. — Prednisolone not only inhibits the changes produced by galactosamine, but it is also capable of inhibiting
marked elevation of the serum levels of aspartate and alanine transaminase and of sorbitol dehydrogenase, and of morphologic signs of
liver damage.
In der vorliegenden Arbeit werden bei der Galaktosamin-Hepatitis biochemische und morphologische Veränderungen beschrieben, die
durch die Verabreichung von Triton WR-1339 beziehungsweise Prednisolon hervorgerufen werden. — Durch Bestimmung der sauren
Phosphatase, N-Acetyl-ß-glucosaminidase, Kathepsin D und sauren Carboxypeptidase in Lysosomenfraktionen konnte sowohl durch
Triton WR-1339 als auch durch Galaktosamin eine Labilisierung der Lysosomenmembran nachgewiesen werden. Gleichzeitige Gabe
von Galaktosamin und Triton WR-1339 führt zu einer verstärkten Labilisierung lysosomaler Membranen. — Nach vorheriger Prednisolon-
Gabe reagiert die Leber nach Galaktosamin-Gabe nur mit einer gering ausgeprägten Entzündung: die Aktivitäten der Aspartat- und
Alanintransaminase sowie Sorbitdehydrogenase im Plasma steigen nur wenig an; lichtmikroskopisch zeigt sich eine geringe entzündliche
Infiltration ohne Nekrosen. Wird Prednisolon nach der Galaktosamin-Applikation gegeben, tritt die Hepatitis abgeschwächt auf.
As in other experimental hepatocellular damages (I, 2)
galactosamine hepatitis is characterized by the presence
of structural alterations in more than one organelle
(2, 3, 4). The difficult task of establishing the so called
"primary target organelle" has so far been accomplished
with only a few toxic agents (5, 6). An increase of
catabolic lysosomal enzyme activities in the rat liver
can be observed after administration of galactosamine
(7), and for this reason, it was of interest to study the
possible role of lysosomes in this type of liver injury by
the application of compounds which can produce
labilization and injury (8, 9, 10) or stabilization (11) of
lysosomes.
The present study deals with morphological and bio-
chemical findings, obtained by application of Triton
WR-1339 and prednisolone to rats with acute galactos-
amine hepatitis. Triton was used because of its capacity
for increasing lysosomal fragility (12), and prednisolone,
because of its well known lysosomal stabilizing effect
(11) and its ability to arrest the development of ex-
perimental hepatic disease (13, 14).
Materials and Methods
Animals
Male Wistar rats (Ivanovas, Kisslegg, Germany) were fed a
standard diet (Altromin R; Altromin GmbH, Lage, Germany)
and water ad libitum. The animals were divided into two ex-
perimental groups:
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Group I
In this group the body weights ranged between 150 and 160 g,
and the animals were divided into the following subgroups2):
A) GalN (4 rats) — a single dose of an aqueous solution (0.45 mol/1)
of galactosamine (purchased as D-galactosamine · HC1 by Carl
Roth OHG, Karlsruhe, Germany) was injected intraperitoneally
at a level of 375 mg/kg;
B) Triton (4 rats) — 1 ml of a Triton WR-1339 (Serva, Heidelberg,
Germany) solution diluted in saline to a concentration of 200 mg/
ml, was injected into the tail vein;
C) GalN plus Triton (9 rats) — galactosamine and Triton were
given simultaneously in the previously mentioned amounts;
D) Prednisolone (4 rats) — 0.15 ml of an aqueous solution of
prednisolone (Deltacortril-Pfizer GmbH, Karlsruhe, Germany)
containing 10 mg/ml were given 4 times intravenously at 3 h
intervals;
E) GalN plus prednisolone (4 rats) — the first dose of prednisolone
was given immediately after galactosamine and the amounts,
routes of administration and subsequent treatment were the same
as stated above;
F) Controls (11 rats) — no treatment.
Group II ·
In this second group, the animals weighed between 180 and
200 g and were also divided into 6 equivalent subgroups. Each
subgroup contained 6 rats with the exception of the GalN plus
Triton subgroup which contained 7. The experiment was designed
in the same way as in Group I, but prednisolone was given sub-
cutaneously at slightly higher dose (up to 0.2 ml). In the GalN
plus prednisolone subgroup prednisolone was also administered
for one day before galactosamine injection (0.2 ml X 4 at 3-hour
intervals).
2) The number of rats indicated in each subgroup corresponds to
those in which total activities of acid phosphatase and N-acetyl-/?-
glucosaminidase were determined. The numbers in which other
enzymes were studied are given in Table 2.
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An additional subgroup of 7 rats treated with galactosaminc and
10 rats \vith combined GalN plus prednisolone treatment as pre-
viously described, was included for determination of serum
enzyme levels.
After 24 h without food but with water, the rats were killed by
exsanguination under light ether anaesthesia. The livers were
removed and divided into several portions for light microscopic
examination and biochemical enzyme determinations.
Light microscopy
Tissue fragments were fixed in 4% neutral buffered formalin and
paraffin sections were stained conventionally with hematoxylin
and eosin, PAS, and PAS after diastase treatment.
Biochemical enzyme determinations
Total activities were determined in liver homogenates prepared,
by homogenizing the samples (0.6—1.5 g) with 9 volumes of
distilled water in an Ultraturrax homogenizer (Jahnke und Kunkel,
S tauf en, Germany).
Tissue fractionation studies were done according to the principles
given by DE Du VE et al. (15) modified by PLATT and KATZEN-
MEIER (16). Before biochemical study samples were frozen and
thawed 3 times.
Acid phospbatase (EC 3.1.3.2) was determined according to the
method described by GIANETTO and DE DUVE (17) but \vith
addition of Triton X-100 as proposed by WATTIAUX and DE DUVE
(18). The liberated inorganic phosphate was measured following
the principle described by FISKE and SUBBAROW (19).
N-Acetjl-ß-glueosaM/nidase (EC 3.2.1.30) was estimated by the
method of VAES and JAQUES modified by VAN HOOF and HERS
(20).
Catbepsin D (EC 3.4.2) was measured by the method of ANSON
(21).
Acid carboxypepfidase (EC 3.4.2.1) was determined as described by
BUDDECKE et al. (22) using the technique proposed by MATHESON
and TATTRIE (23).
One unit of hydrolytic activity represents the amount of enzyme
needed to degrade 1 micromole of substrate per minute at 37°C
(20). Protein was measured by means of the Biuret technique (24).
Standard procedures were used for determination of serum levels
of aspartate awinotransferase (EC 2.6.1.1) (25), alanine aminotrans-
j-erase (EC 2.6.1.2) (26) and sorbitol dthydrogmase (EC 1.1.1.14) (27).
Histological examination was performed in all animals. Deter-
minations of cathepsin D and acid carboxypeptidase were only
done in rats from experimental Group I. Total activities of acid
phosphatase and N-acetyl-/?-glucosaminidase were also determined
in this group and repeated when fractionation studies of these two
enzymes were done in experimental Group II.
Results
Light microscopic study
The histological findings were similar in both groups.
In the galactosamine treated subgroups the usual
findings were noted: mainly disseminated single cell
and spotty necroses; activation of mesenchymal cells,
and inflammatory infiltrates not only in the parenchyma,
but also in the portal tracts (Fig. la).
The hepatocytes of Triton-treated animals showed no
alterations. The KUPFFER cells were moderately in-
creased in number but no evidence of erythrophago-
cytosis was found.
The animals given galactosamine plus Triton displayed
the most severe hepatic lesions. Although the lobular
architecture was preserved, the areas of parenchymal
necroses were extensive and inflammatory cells were
more numerous than with galactosamine alone (Fig.
Fig. la
Liver of rat 24 h after administration of galactosamine. Hematoxylin
and eosin, x 125
Fig. I b
Liver of a galactosamine plus Triton-treated rat. Extensive paren-
chymal necroses and numerous inflammatory cells are evident Hema-
toxylin and eosin, x 125
Fig. Ic
Liver of a galactosamine plus prednisolone-treated rat. Single cell
eosin, x 125
necroses and KUPFFER cell hyperplasia are only discrete. Note the
absence of inflammatory cells. Hematoxylin and
1 b). Conspicuous edema of the portal tracts as well as
focal parenchymal hemorrhages appeared as additional
features.
When prednisolone was given in addition to galactos-
amine, the lesions were similar to those present in the
galactosamine-treated. animals, but much less marked
(Fig. Ic). Entire lobules free of necroses could be
identified. Variations in hepatocytic size and shape, as
well as variations in the staining quality of the cyto-
plasm, were less conspicuous. No differences could be
detected between the animals pretreated with predni-
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solone (Group II) and those without previous admin-
istration of the corticosteroid (Group I).
The prednisolone-treated subgroups showed fine vacu-
olated fatty degeneration, limited mostly to the lobular
periphery.
Biochemical enzyme determinations
Serum levels of aspartate, and alanine transaminase, and
of sorbitol dehydrogenase of those animals treated with
grvlactosamine plus prednisolone were much lower
than those present in the animals treated with galactos-
amine alone (Tab. 1). Mean values for the three enzymes
were almost normal.
Total activities of cathepsin D and acid carboxypeptid-
ase were decreased in the animals treated with galactos-
amine. Both catabolic enzymes were increased in the
supernates from the rats in which galactosamine plus
Triton were given. Elevations of enzyme activities were
also present in the supernates from the galactosamine-
treated rats. When Triton was injected alone, only
cathepsin D was increased (Tab. 2).
In experimental Group total activities of acid phos-
phatase and N-acetyl-/?-glucosaminidase, whether rel-
Tab. I
Serum enzyme activities [U/l]a















ated to protein content or wet weight, showed similar
values with exception of an increase of acid phos-
phatase in the galactosamine-treated rats. Both enzymes
were elevated in the supernates from the GalN plus
Triton-treated subgroup, but only N-acetyl-ß-glucos-
aminidase showed increased acitivity in the supernates
from the animals treated with galactosamine alone or
Triton alone (Tab. 3).
In both groups, enzyme activities of the combined
galactosamine plus prednisolone treatement were com-
parable to those found in the control animals.
Discussion
The present study indicates that Triton WR-1339 is
capable of aggravating the lesions produced by galactos-
amine in the liver of rats. It also suggests that a protec-
tive effect can be obtained by administering predni-
solone either simultaneously or before giving galactos-
amine.
Total activities of the lysosomal enzymes acid phos-
phatase, N-acetyl-ß-glucosaminidase, cathepsin D, and
acid carboxypeptidase in the liver homogenates were
determined on the premise that lysosomal damage
induced by galactosamine or galactosamine plus Triton
would liberate lysosomal enzymes. Only cathepsin D
and acid carboxypeptidase were found to be decreased
in the galactosamine treated animals, but acid phos-
phatase was increased in the same subgroup.
The use of fractionation techniques demonstrates that
the significant increase of several enzymes in the majority








































































































p of paired samples (vs controls) a < 0.005; b < 0.0025; c < 0.0005
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amine and/or Triton reflect the release of enzymes from
lysosomes. This confirms previous findings in which
cathepsin D and acid carboxypeptidase showed similar
changes 25 h after the administration of galactosamine
(7). An increase in lysosomal enzyme activities in the
liver is not due to an enhanced activation of mesenchymal
cells, because normal enzyme values could be measured
in liver diseases with mesenchymal activation, and also
in isolated leucocytes stimulated by inflammation
(28, 29).
Whether the liberation of these enzymes is the result of
primary damage already present in the early stages of
liver injury, or is only an expression of cell necroses (8),
is difficult to establish in this experiment. But in any
case, the increase of 3 of the 4 assayed enzymes in the
supernates from those animals treated with Triton alone
cannot be attributed to focal necroses or to the con-
currence of an extrahepatic cell population, since
neither necroses nor inflammatory infiltrates were
observed.
The absence of enzyme variations in the animals treated
with galactosamine and prednisolone indicates that
corticosteroids have a protective role. Furthermore,
the impressive inhibition of an increase of serum levels
of aspartate and alanine transaminase and of sorbitol
dehydrogenase observed when prednisolone is given
together with galactosamine constitutes additional
evidence for the protective role of prednisolone. To
what degree this protection is achieved with parti-
cipation of other organelles, including the cell mem-
brane, is not known with certainty (11, 30). The
stabilizing effect of corticosteroids in connection with
lysosomes has been demonstrated in the liver but
without any relation at all to toxic agents (31), and in
in vitro experiments (30). Confirmatory evidence based
on the antagonistic effects of vitamin A and cortisone
indicate that this can also be accomplished in vivo (32).
The increase in total activities of acid phosphatase after
administration of galactosamine alone may suggest new
synthesis as the result of an early regenerative response
to the diffuse damage (28). Increased synthesis of N-
acetyl-/8-glucosaminidase, suggested to be the conse-
quence of parenchymal cell division, has been found in
rats 24 h after partial hepatectomy (33).
If the aggravating effect of Triton on the hepatic
necroses induced by galactosamine is due at least
partially to lysosomal injury, it would seem to support
the assumption that alterations of this organelle play a
role in the conversion of spotty viral hepatitis to massive
hepatic necroses (10). On the other hand further studies
of the protective role of corticosteroids using galactos-
amine induced hepatitis as an experimental model
might be useful in order to ckrify the inconsistency in
the response of human viral hepatitis to corticosteroid
therapy.
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